Utilizing a Novel Method to Map Sources of Atrial Fibrillation

NCT ID: NCT02523534

Last Updated: 2023-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an electrogram mapping study that tests the ability of a new signal processing technique called electrogram morphology recurrence mapping to locate drivers in participants with atrial fibrillation. This study will also test the hypothesis that there are non-invasive markers that can predict driver location. Electrogram mapping will be performed in participants undergoing ablation for persistent atrial fibrillation. These participants will have a cardiac MRI and 12-lead ECG prior to the ablation procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF) has been described as a new emerging epidemic currently affecting around 1% of the population. Risk of AF increases with age and as the elderly continue to comprise a larger percentage of the population in the United States, the health burden of AF continues to increase. Some estimates project nearly 16 million cases of AF in the US alone by 2050. The economic burden of AF has been estimated to be between $6-26 billion. AF is a significant risk factor for stroke if left untreated as well as mortality. The diagnosis and treatment of AF have therefore become an important aspect of cardiovascular medicine.

Current pharmacological treatments for AF have modest efficacy and suffer from potentially life-threatening side effects. Current ablative and surgical approaches to AF, though somewhat more successful, use an anatomic, 'one-size fits all' strategy (with some minor variations) that does not address the specific mechanisms underlying this complex arrhythmia. The pulmonary veins have been shown to be a common location of AF triggers. Thus, the most common approach for catheter ablation involves the isolation of the pulmonary veins, such as the wide area circumferential pulmonary vein ablation strategy. The lack of consideration of specific sources may be, at least in part, responsible for post- ablation arrhythmias occurring in up to 40% of patients who undergo pulmonary vein ablation. However, while ablation/surgical success has been shown to increase with more extensive ablation/surgery in the atria, the latter comes at the cost of significant "collateral damage" to the atrial myocardium as well as to surrounding structures, with an accompanying increase in the risk of complications and a decrease in atrial function. The time and cost to perform these procedures is also significant. Thus, catheter and surgical ablation strategies tailored to the specific arrhythmia origin of a patient's AF would have a significant impact on the ability to treat this arrhythmia.

The investigator's laboratory has developed a novel electrogram morphology recurrence analysis to observe the nonlinear dynamics of AF activation. This technique to map AF activation is based on the hypothesis that AF electrograms with morphologies that are highly recurrent and that have short cycle lengths represent the locations of stable AF sources. The investigator's preliminary data show that when the highest recurrence percentage or shortest recurrence cycle length occurs in the left atrium in patients undergoing pulmonary vein-based ablation, the patients has a much higher chance to stay in sinus rhythm post-ablation than when the highest recurrence percentage or shortest recurrence cycle length occur in the right atrium. Cycle length of all activations was not a predictor of outcomes. High resolution electrical mapping of AF in the canine atria showed that the shortest recurrence cycle length sites correspond to areas containing rotors. Thus, these preliminary data provide strong evidence that morphology recurrence mapping is able to identify the locations of AF sources.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recurrence Mapping

Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.

Group Type EXPERIMENTAL

MRI

Intervention Type PROCEDURE

MRI images will be taken in conjunction with the clinically indicated cardiac MRI.

ECG

Intervention Type PROCEDURE

ECG readings will be taken prior to the participants clinically indicated procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

MRI images will be taken in conjunction with the clinically indicated cardiac MRI.

Intervention Type PROCEDURE

ECG

ECG readings will be taken prior to the participants clinically indicated procedure.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Magnetic Resonance Imagining Electrocardiogram

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female, At least 21 years of age.
* Subjects with persistent AF undergoing a first catheter ablation procedure.

Exclusion Criteria

* Inability to sign consent.
* Patients with a life expectancy \<1 year.
* Previous ablation of the atria
* Pregnant women and women that are breast feeding.
* Subjects with contraindication to MRI such as cochlear implants, ocular foreign body (e.g. metal shavings), brain aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker or defibrillator.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jason Ng, PhD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01HL125881-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STU00200809

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase-Aligned Atrial Fibrillation Mapping
NCT06892561 ACTIVE_NOT_RECRUITING
Specific Electrophenotypes in Atrial Fibrillation
NCT05366530 ACTIVE_NOT_RECRUITING